Active Ingredient History

  • Now
Anagrelide is an orally active quinazinolone derivative that was originally developed as an antiplatelet drug. The drug inhibits cyclic nucleotide phosphodiesterase III (PDEIII) and phopholipase A2, which is thought to cause the side effects of vasodilation, positive inotropism, reduced platelet aggregation. However, significant inhibition of platelet aggregation is observed only at doses of anagrelide higher than those required to reduce platelet count. It is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders. Commonly reported side effects of anagrelide include: abdominal pain, dizziness, headache, nausea, and palpitations. Other side effects include: back pain, fever, tachycardia, vomiting, and anorexia. There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption. Anagrelide is an inhibitor of cyclic AMP PDE III. The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$0.7067 - $7.5537
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3h)-one hydrochloride | agrelin | agrylin | anagrelida | anagrelide | anagrelide hcl | anagrelide hydrochloride | anagrelide hydrochloride hydrate | anagrelide hydrochloride monohydrate | anagrelidum | bl 4162a | bl-4162a | imidazo(2,1-b)quinazolin-2(3h)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | spd422 | thromboreductin | xagrid


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue